Citi opened a “90-day positive catalyst watch” on shares of Zimmer Biomet (ZBH) while keeping a Neutral rating on the name with a $120 price ...
Zimmer Biomet had a strong 2024, bolstering its product lines and staying on top of orthopedic medtech trends.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback